Abstract: Covid 19 is a serious virus produces pandemic with great lethality. The present invention teaches that if the Covid 19 virus cannot enter the lung or other body cells that infection of Covid 19 can be reduced. The inventive element of the present invention is to saturate the megalin/cubilin receptor with cobalamin (vitamin B 12) that are specific for Covid 19 virus. This treatment using cobalamin may include additional compounds with increased isoelectric points.

Abstract: The invention is a bag-scoop device to collect cat litter waste. The scoop part is a flat construct which readily folds and squeezes into a disposable scoop or shovel. The are holes in the dish of the shovel to sieve out small litter particles and retains the aggregated waste balls. The manufactured invention includes a bag that contains the scoop and attached frame to hold the bag open to receive the aggregated waste balls. The frame automatically is placed in the opening of the bag as the scoop is removed. In a second option a scraper part is attached to the scoop.

Abstract: Increased positive charge of compounds or agents leads to increased glomerular filtration, increased binding by positively charged agents by the cells of the proximal tubules and decreased digestion of the reabsorbed materials. The present invention concerns the use of non-toxic positively charged materials to saturate binding sites on the proximal tubular brush border. If the binding sites on the brush border are saturated, then there should be decreased binding and absorption of the toxic agents by the proximal tubular renal cells. Specifically the invention is the use of combination of therapeutic positively charged agents comprising one or more of the following compounds; pyridoxal, niacin, thiamine and their relatively non-toxic analogs, amprolium, and isoniazid. These compounds are administered prior to the dosing of such positively charged therapeutics such as Trasylol® (aprotinin), cisplatin. or antimicrobiological peptides such as reported in patent application publication 2005/0065072.

Abstract: A hypodermic syringe is disclosed which facilitates both the transportation of a fluid specimen therein and the ready accessibility of the specimen in the syringe. The hypodermic syringe is provided with a port in the syringe barrel proximate the needle neck of the barrel. Location of the port in this area facilitates the introduction of sampling instruments into the interior chamber of the syringe. A fluid-tight cap is provided for the port. A boss is also provided spaced inwardly along the exterior of the barrel of the syringe near the plunger opening of the syringe, to thereby incline the syringe to promote pooling of specimen fluids in the area of the port. A rigid protective cover for a hypodermic needle mounted on the needle neck of the syringe is removably received on the barrel of the syringe, and is spaced radially from the neck, and surrounds the hypodermic needle to protect the needle during transport.

Abstract: Novel medicaments and methods of use thereof are disclosed for reducing in a human or an animal nephrotoxic effects associated with positively charged molecules or agents. The positively charged molecules or agents may be endogenous or exogenous to the human or animal. Examples of endogenous positively charged molecules or agents include proteins or myoglobin, whereas exogenous positively charged molecules and agents may be pharmaceuticals, such as those derived from the aminoglycoside antibiotic family. The medicament comprises a positively charged (cationic) substance which is preferably substantially inert and substantially secreted by the proximal tubules of the kidney. An example of a positively charged (cationic) substance that is substantially inert is amprolium. In addition, the medicament may include a pharmaceutical, such as an aminoglycoside antibiotic for treating bacterial infection.

Abstract: An improved label is disclosed comprising two semi-rigid cards connected to each other by means of a thin flexible member. Each of the cards has an adhesive portion covered by a release paper and a non-adhesive portion. One end of the flexible member is attached to a respective non-adhesive portion to thereby connect the cards. The adhesive portion and the non-adhesive portion of each card are separable from each other along a perforation which facilitates the disconnection of the cards when desired.The present invention finds particular application and advantage with laboratory specimen containers. In use, one card is adhesively secured to identifying material, such as a pad of laboratory order slips, and the other card is adhesively secured to a specimen container. The identifying material is thus mechanically attached to the container though in spaced relation thereto by virtue of the flexible interconnecting member.

Abstract: A device for grinding and transporting solids, such as surgical tissue samples, is disclosed which comprises in a preferred form a container having an upper portion defining an upwardly open top and a grinder receivable in the interior of the container. The grinder has a grinding head having a shape closely conforming to the shape of the container interior bottom, a cap that is screwed onto the upper portion of the container, and a compressible intermediate and body section joining the grinding head and the grinder top. A reservoir containing bacterial maintenance fluid, such as a frangible glass ampul containing such fluid, is carried within the compressible intermediate section.The grinding device has a grinding configuration wherein the grinding head is received in the bottom interior of the container with the cap adjacent the container upper portion. In use, surgical tissue is placed in the container and the device is placed in the grinding configuration.

Abstract: Storage stable aqueous batters are provided for use in the preparation of leavened culinary products. To the batter is added a quantity of powdered edible acid sufficient to maintain the pH at an acid level below about 5 to inhibit microbial growth. Particles of alkaline leavening agent, encapsulated in a water insoluble coating are also added to the batter. The alkaline leavening agent is capable of dispersing in the batter ingredients at a cooking temperature safely above the storage temperature to release the leavening agent into the acid batter mixture, thereby neutralizing the acid, and leavening the product. The batter premixture is storable with preservation against microbial growth, and the acid-base leavening system isolated to avoid pre-reaction prior to preparing a leavened product.